CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


2: Placebo ComparatorWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)


Name (Synonyms) Correlation
drug163 Anakinra Prefilled Syringe Wiki 1.00
drug17 1: ILT101 Wiki 1.00
drug2536 Tocilizumab Prefilled Syringe Wiki 1.00
drug2352 Standard-of-care treatment Wiki 1.00

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D055371 Acute Lung Injury NIH 0.10
D012127 Respiratory Distress Syndrome, Newborn NIH 0.10
D012128 Respiratory Distress Syndrome, Adult NIH 0.09

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19

The purpose is to demonstrate the efficacy of low-dose interleukin 2 (Ld-IL2) administration in improving clinical course and oxygenation parameters in patients with SARS-CoV2-related ARDS.

NCT04357444 COVID 19 Drug: 1: ILT101 Drug: 2: Placebo Comparator
MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury

Primary Outcomes

Measure: The PaO2/FiO2 ratio at D11

Time: at Day11

Secondary Outcomes

Measure: Changes in Tregs between Baseline and Day 7 (expressed in %)

Time: at Day0 and Day7

Measure: Number of days alive with oxygen therapy within 28 days

Time: at Day28

Measure: Maximal oxygen rate within 28 days

Time: at Day28

Measure: Number of days alive free of invasive or non-invasive ventilation within 28 days

Time: At Day28

Measure: Number of days alive outside ICU within 28 days

Time: at Day28

Measure: Number of days alive outside hospital within 28 days

Time: at Day28

Measure: Time (in days) from randomization to death

Time: through study completion at day 28

Measure: Mortality rate at D28

Time: at Day28

Measure: Difference between CRP levels at randomization and at Day 7 (or at the time of discharge if occurs before Day 7)

Time: at Day0 and Day7 or at the time of discharge

Measure: Use of antibiotics for respiratory (proved or suspected) infection within 28 days

Time: at Day28

Measure: Number of prone positioning sessions

Time: throughout the follow up period at day 28

Measure: Changes in Tregs during the different visits between baseline and day 28

Time: at Day0, 5, 7, 11, 14 and Day28

Description: To evaluate selected immune and inflammatory markers: Serum concentrations of cytokines and soluble factors related to the immune response and inflammatory processes will be evaluated and compare to baseline by multiplex immunoprofiling to analyse a larger number of molecules including at least IFNα2, IFNγ, IL-1α, IL-1β, IL-1RA, IL-2, IL-6, IL-8, IL-10, IL-17, TNFα, TNFβ, VEGF-A, TGF-beta, S-RAGE, SP-A, SP-D, Angiopoétine 1 and KGF.

Measure: Cytokines analysis on plasma samples at Day 0, 7 and 14

Time: at Day 0, 7 and 14

Measure: Tregs numbers during induction period and throughout the follow up period at day 5, 7, 11, 14 and 28 compared to baseline before the first IL-2 injection.

Time: at Day0, 5, 7, 11, 14 and Day28

Measure: Tregs percentages during induction period and throughout the follow up period at day 5, 7, 11, 14 and 28 compared to baseline before the first IL-2 injection.

Time: at Day0, 5, 7, 11, 14 and Day28

Description: Cellular components will be analysed by flow cytometry covering (i) most of the innate and adaptive immune cells including Tregs, T helper cell subsets including follicular helper cells, B cell subsets, NK cell subsets, (ii) the associated relevant markers of activation/function/differentiation, tissue migration, as well as (iii) unconventional lymphoid cells (NKT/MAIT, innate lymphoid cells), myeloid-derived suppressor cells, classical and non-classical monocytes and dendritic cells (mDC1/2, pDC).

Measure: Deep Immunophenotyping of Cellular components in blood samples at Day 0, 7, and 14

Time: at Day0, 7 and Day14

Measure: T cell repertoire on Treg, after sorting from blood at Day 7 and Day 14 and compared to baseline

Time: at Day0, 7 and Day14

Measure: T cell repertoire on Teff (CD4 and CD8) after sorting from blood at Day 7 and Day 14 and compared to baseline

Time: at Day0, 7 and Day14

Measure: Single cells sequencing will be performed in BAL at Day 7 and Day 14 and compared to baseline.

Time: at Day0, 7 and Day14


No related HPO nodes (Using clinical trials)